NeoPath Plans Expanded U.S. AutoPap Features Following Canadian Approval
This article was originally published in The Gray Sheet
Executive Summary
NeoPath plans a regulatory submission next year to expand the U.S. indications for its AutoPap automated pap smear screening system following Canadian approval of additional features to the system, the company reported Feb. 22.